American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 41-50 , January 2009

Randomized Placebo-Controlled Trial Assessing a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Plasma Asymmetric Dimethylarginine Concentration in Mild to Moderate CKD

  • Prabath W.B. Nanayakkara, MD

      Affiliations

    • Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
    • Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationAddress correspondence to Prabath W.B. Nanayakkara, MD, Department of Internal Medicine, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • Jessica C. Kiefte-de Jong, MSc

      Affiliations

    • Institute of Health Sciences, Faculty of Earth and Life Sciences, VU University, Amsterdam, The Netherlands
    • ,
  • Piet M. ter Wee, MD, PhD

      Affiliations

    • Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Coen D.A. Stehouwer, MD, PhD

      Affiliations

    • Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Frans J. van Ittersum, MD, PhD

      Affiliations

    • Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands
    • ,
  • Margreet R. Olthof, MSc, PhD

      Affiliations

    • Institute of Health Sciences, Faculty of Earth and Life Sciences, VU University, Amsterdam, The Netherlands
    • ,
  • Tom Teerlink, MD, PhD

      Affiliations

    • Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Jos W.R. Twisk, MD, PhD

      Affiliations

    • Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Coen van Guldener, MD, PhD

      Affiliations

    • Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands
    • ,
  • Yvo M. Smulders, MD, PhD

      Affiliations

    • Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
    • Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands

Received 24 February 2008 ,Accepted 9 June 2008.

References 

  1. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023–1030
  2. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575
  3. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet. 2001;358:2113–2117
  4. Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: An epidemiological study. Atherosclerosis. 2007;191:206–210
  5. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation. 1999;99:1141–1146
  6. Nanayakkara PW, Teerlink T, Stehouwer CD, et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 2005;68:2230–2236
  7. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13:490–496
  8. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med. 2005;10(suppl 1):S27–S33
  9. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092–3095
  10. Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation. 2003;108:933–938
  11. Piroddi M, Depunzio I, Calabrese V, et al. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids. 2007;32:573–592
  12. Holven KB, Haugstad TS, Holm T, et al. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr. 2003;89:359–363
  13. Schmitt B, Wolters M, Kressel G, et al. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis. 2007;193:168–176
  14. Spoelstra-de Man AM, Teerlink T, Brouwer CB, et al. No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. Clin Endocrinol (Oxf). 2006;64:495–501
  15. Ziegler S, Mittermayer F, Plank C, et al. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab. 2005;90:2175–2178
  16. Saran R, Novak JE, Desai A, et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): A pilot study. Nephrol Dial Transplant. 2003;18:2415–2420
  17. Lu TM, Ding YA, Leu HB, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004;94:157–161
  18. Valkonen VP, Laakso J, Paiva H, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events (Does statin treatment influence plasma ADMA levels?). Atherosclerosis Suppl. 2003;4:S19–S22
  19. Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol. 2008;21:38–44
  20. Nanayakkara PW, van GC, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: Results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med. 2007;167:1262–1270
  21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  22. de JS, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem. 2006;353:287–289
  23. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem. 1995;41:991–994
  24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  25. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487–1494
  26. Twisk JW. Longitudinal data analysis (A comparison between generalized estimating equations and random coefficient analysis). Eur J Epidemiol. 2004;19:769–776
  27. Teerlink T. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:21–29
  28. Morimoto H, Nakao K, Fukuoka K, et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant. 2005;20:2775–2782
  29. Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end-stage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272–1280
  30. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87:99–105
  31. Jiang JL, Li Ns NS, Li YJ, et al. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol. 2002;135:1175–1182
  32. Boaz M, Smetana S, Weinstein T, et al. Secondary Prevention With Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–1218
  33. Sydow K, Schwedhelm E, Arakawa N, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: Effects of L-arginine and B vitamins. Cardiovasc Res. 2003;57:244–252
  34. Stam F, van GC, ter Wee PM, et al. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: Association with S-adenosylhomocysteine. Am J Physiol Renal Physiol. 2004;287:F215–F223
  35. Herrmann W, Obeid R. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients. Clin Chem Lab Med. 2005;43:1039–1047
  36. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: The potential role of ADMA. Atherosclerosis Suppl. 2003;4:S61–S65
  37. Lobo A, Naso A, Arheart K, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol. 1999;83:821–825
  38. Del RD, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316–328
  39. Comporti M, Signorini C, Arezzini B, et al. F2-isoprostanes are not just markers of oxidative stress. Free Radic Biol Med. 2008;44:247–256
  40. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13:170–176
  41. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456–2461
  42. Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17:1128–1134
  43. Closs EI, Basha FZ, Habermeier A, et al. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997;1:65–73

 Originally published online as doi:10.1053/j.ajkd.2008.06.016 on September 16, 2008.

 Trial registration: http://clinicaltrials.gov; study number: NCT00384618.

PII: S0272-6386(08)01101-3

doi: 10.1053/j.ajkd.2008.06.016

American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 41-50 , January 2009

Article Tools

* Image Usage & Resolution